Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria

Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria

Patients with transthyretin cardiac amyloidosis (TTR CA) suffer from impaired exercise capacity, have a poor quality of life (QoL), and approved treatments are lacking. Stimulators of the soluble guanylate cyclase are promising new pharmaceuticals in the treatment armamentarium of heart failure pati...

Full description

Bibliographic Details
Main Authors: Franz Duca, Stefan Aschauer, Caroline Zotter-Tufaro, Christina Binder, Andreas A. Kammerlander, Benedikt Börries, Hermine Agis, Renate Kain, Christian Hengstenberg, Julia Mascherbauer, Diana Bonderman
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Pulmonary Circulation
Online Access:https://doi.org/10.1177/2045894019849394

Internet

https://doi.org/10.1177/2045894019849394

Similar Items